10x Genomics Insiders Sell $12M as Stock Tops $85
TXG shares have surged to $85.71 — 51% above the analyst consensus price target — after news outlets attributed the move to an AI partnership and a legal win, yet the company's CEO and CFO have sold a
10x Genomics Insiders Sell $12M as Stock Tops $85
NEW YORK, September 28 —
10x Genomics, Inc. (TXG) trades at $85.71, a 51% premium to analyst consensus, after news outlets reported an AI partnership and a legal win as catalysts. Three days before those reports circulated, CEO Serge Saxonov sold 25,000 shares at $78 to $82; the CFO had sold 46,388 shares at $63 to $65 two weeks prior.
- Stock 51% above analyst consensus target of $56.60; forward P/E is 779.2x on trailing EPS of -$0.59.
- Total insider open-market sales: $12.24 million over 90 days; zero open-market purchases recorded.
- Trailing revenue down 12.7% to $620 million; free cash flow positive at $180 million trailing.
The Catalyst No Filing Confirms
News coverage from September 25-26 attributed TXG's rally to an AI partnership and a legal win, per multiple outlets. No SEC filings in the 120-day evidence window confirm the details of either event. That absence matters: at $85.71, the stock carries a 779.2x forward earnings multiple on a business that sells Chromium single-cell analysis instruments and Visium spatial transcriptomics platforms to academic, biopharmaceutical, and government labs, while trailing revenue fell 12.7% over the past year. A premium priced on unconfirmed catalysts against a shrinking revenue base is a fragile foundation.
What the Selling Pattern Reveals
Per filings, CEO Saxonov sold 25,000 shares on September 22 in five tranches at $78.23 to $82.36, collecting approximately $2.03 million. CFO Adam Taich had sold 46,388 shares two weeks earlier at $63.68 to $65.26, collecting roughly $3 million. Across 90 days, total insider open-market sales reached $12.24 million with zero purchases. Insider ownership is 1.5% of shares outstanding, meaning the executives who know the AI partnership and legal win best chose to cut already-thin positions into the rally, not add to them.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| TXG | $11.2B | 779.2x | +655.8% |
| TWST | $12.1B | n/a | +577.1% |
| BEAM | $2.5B | n/a | +1.5% |
| PACB | $504M | n/a | +29.6% |
| VCYT | $3.7B | 23.3x | +35.2% |
| GH | $23.8B | n/a | +185.9% |
What Would Have to Be True
The bull case rests on a genuine EPS beat streak: four consecutive quarters of positive surprises, including a 240% beat in the August 8-K, show real cost discipline. Free cash flow of $180 million and $550 million in cash against $80 million of debt give the company real options. But a 779.2x forward earnings multiple requires revenue to turn positive, and a DCF calculator quickly shows how heroic the growth assumptions must be. With 18.8% short interest, next quarter's revenue line is the single figure that changes the thesis. Run the free 10x Genomics, Inc. deep-dive for the latest numbers.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
TXG shares have surged to $85.71 — 51% above the analyst consensus price target — after news outlets attributed the move to an AI partnership and a legal win, yet the company's CEO and CFO have sold a combined $5 million in open-market shares over the past three weeks alone, part of $12.24 million in insider sales over 90 days with zero purchases recorded.